This treatment is in clinical trials and has not been approved by the FDA or any regulatory authority. It is not available for prescription. Current stage: Phase 3 complete; FDA NDA under review — PDUFA date April 10, 2026. Estimated approval: April 2026 (FDA decision expected April 10, 2026 — not yet confirmed) — subject to change.
Orforglipron
Eli Lilly
A small-molecule oral GLP-1 receptor agonist that has completed Phase 3 trials for obesity. The FDA NDA is currently under review with a PDUFA decision date of April 10, 2026. Oral Wegovy (semaglutide pill) was the first oral GLP-1 approved for weight loss (December 2025) — orforglipron's key differentiator is that unlike oral Wegovy, it has NO food or water restrictions. You can take it any time without planning around meals.
Quick read · 4 min
- •Orforglipron is an investigational drug — it has not yet been approved by any regulatory authority
- •Best trial result so far: up to 12.4% average weight loss
- •Current stage: Phase 3 complete; FDA NDA under review — PDUFA date April 10, 2026
- •Expected approval: April 2026 (FDA decision expected April 10, 2026 — not yet confirmed) — this is an estimate and not confirmed
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026
How it works
A small-molecule (non-peptide) GLP-1 receptor agonist. Unlike peptide GLP-1 drugs (semaglutide, liraglutide) that require injection, orforglipron is a small organic molecule that can be absorbed through the gut wall. It activates the same GLP-1 receptors in the brain and pancreas as injectable drugs, but in a daily pill form with no food restrictions.
Phase 3 trial results
In the following Phase 3 trials, participants were randomly assigned to Orforglipron or a dummy pill.
In the ATTAIN-1 trial, 12.4% mean weight loss (highest dose, 36 mg). 59.6% achieved ≥10% loss.
In the ATTAIN-2 trial, 10.5% weight loss (highest dose). HbA1c reduced by 1.8%.
In the ATTAIN-MAINTAIN trial, Maintained weight loss from prior injectable treatment — average difference of only 0.9 kg vs. continuing injectable. Met all primary endpoints.
In the ACHIEVE-1 trial, 7.9% weight loss (highest dose). HbA1c reduced 1.3–1.6%.
Side effects (early-stage data)
Frequencies from Phase 2 trial data. Final Phase 3 safety profile may differ.
Notable findings
- ✓No injection required — a daily pill with no food/water restrictions
- ✓Eli Lilly states it can be manufactured globally at lower cost than peptide-based drugs
- ✓91% of prediabetic participants reached near-normal blood sugar vs. 42% placebo (ATTAIN-1)
- ✓Maintained weight from prior injectable GLP-1 treatment when switched (ATTAIN-MAINTAIN trial)
Community insights
These are personal experiences shared in public online communities — not medical advice.
“The main excitement is that this is a pill you can take without planning around food — unlike oral semaglutide which requires 30 minutes fasting before and after.”
“The 12.4% weight loss is less than weekly tirzepatide or semaglutide injections, but the pill convenience factor could be a game-changer for people unwilling to inject.”
Sources & references
- [1]ATTAIN-1Adults with obesity or overweight with comorbidities, no type 2 diabetes · 72 weeks12.4% mean weight loss at 36 mg dose. 59.6% achieved ≥10% loss. Nausea 29–36% vs. 10% placebo; vomiting 13–24% vs. 4% placebo.New England Journal of Medicine (2025) ↗
- [2]ATTAIN-2Adults with obesity and type 2 diabetes · 72 weeks10.5% weight loss at highest dose. HbA1c reduced by 1.8%. Consistent GI safety profile with injectable GLP-1 class.The Lancet (2025) ↗
- [3]ATTAIN-MAINTAIN (transition from injectable)Adults who had been on Wegovy or Zepbound switching to orforglipron · 52 weeksWeight maintained following switch — average difference of 0.9 kg vs. those continuing injectable GLP-1. All primary endpoints met.Eli Lilly press release (2025) ↗